Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Dermot G Neely

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Atherosclerosis|September 15, 2005
Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rateColin A Graham, Brian P McIlhatton, Claire W Kirk, et al.
Annals of Clinical Biochemistry|January 10, 2025
Standardising lipid testing and reporting in the United Kingdom; a joint statement by HEART UK and The Association for Laboratory MedicineJulia S Kenkre, Tina Mazaheri, R Dermot G Neely, et al.
Clinical Chemistry|October 3, 2009
Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9Steve E Humphries, R Dermot G Neely, Roslyn A Whittall, et al.
Gut|October 14, 2010
Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infectionSimon H Bridge, David A Sheridan, Daniel J Felmlee, et al.
Journal of Hepatology|March 15, 2012
Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: evidence for an association with interferon sensitivityDavid A Sheridan, Simon H Bridge, Daniel J Felmlee, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 15, 2013
Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trialDavid A Sheridan, Simon H Bridge, Mary M E Crossey, et al.
Gastroenterology|August 5, 2010
Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particlesDaniel J Felmlee, David A Sheridan, Simon H Bridge, et al.
Frontiers in Immunology|April 4, 2025
Autoantibodies to apolipoprotein A-I in hepatitis C virus infection: a role in disease progression?Simon H Bridge, Sabrina Pagano, John K Lodge, et al.
Atherosclerosis|November 10, 2019
HEART UK consensus statement on Lipoprotein(a): A call to actionJaimini Cegla, R Dermot G Neely, Michael France, et al.
Journal of Hepatology|December 3, 2014
PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolismSimon H Bridge, David A Sheridan, Daniel J Felmlee, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Atherosclerosis|September 15, 2005
Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rateColin A Graham, Brian P McIlhatton, Claire W Kirk, et al.
Annals of Clinical Biochemistry|January 10, 2025
Standardising lipid testing and reporting in the United Kingdom; a joint statement by HEART UK and The Association for Laboratory MedicineJulia S Kenkre, Tina Mazaheri, R Dermot G Neely, et al.
Clinical Chemistry|October 3, 2009
Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9Steve E Humphries, R Dermot G Neely, Roslyn A Whittall, et al.
Gut|October 14, 2010
Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infectionSimon H Bridge, David A Sheridan, Daniel J Felmlee, et al.
Journal of Hepatology|March 15, 2012
Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: evidence for an association with interferon sensitivityDavid A Sheridan, Simon H Bridge, Daniel J Felmlee, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 15, 2013
Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trialDavid A Sheridan, Simon H Bridge, Mary M E Crossey, et al.
Gastroenterology|August 5, 2010
Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particlesDaniel J Felmlee, David A Sheridan, Simon H Bridge, et al.
Frontiers in Immunology|April 4, 2025
Autoantibodies to apolipoprotein A-I in hepatitis C virus infection: a role in disease progression?Simon H Bridge, Sabrina Pagano, John K Lodge, et al.
Atherosclerosis|November 10, 2019
HEART UK consensus statement on Lipoprotein(a): A call to actionJaimini Cegla, R Dermot G Neely, Michael France, et al.
Journal of Hepatology|December 3, 2014
PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolismSimon H Bridge, David A Sheridan, Daniel J Felmlee, et al.
Pageof 3